BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35877722)

  • 1. Design, Synthesis and Evaluation of Novel Phorbazole C Derivatives as MNK Inhibitors through Virtual High-Throughput Screening.
    Jin X; Li M; Qiu T; Yu R; Jiang T
    Mar Drugs; 2022 Jun; 20(7):. PubMed ID: 35877722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in developing MNK inhibitors.
    Jin X; Yu R; Wang X; Proud CG; Jiang T
    Eur J Med Chem; 2021 Jul; 219():113420. PubMed ID: 33892273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
    Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
    Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.
    Korneeva NL; Song A; Gram H; Edens MA; Rhoads RE
    J Biol Chem; 2016 Feb; 291(7):3455-67. PubMed ID: 26668315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MAP kinase-interacting kinases regulate cell migration, vimentin expression and eIF4E/CYFIP1 binding.
    Beggs JE; Tian S; Jones GG; Xie J; Iadevaia V; Jenei V; Thomas G; Proud CG
    Biochem J; 2015 Apr; 467(1):63-76. PubMed ID: 25588502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening.
    Mishra RK; Clutter MR; Blyth GT; Kosciuczuk EM; Blackburn AZ; Beauchamp EM; Schiltz GE; Platanias LC
    Chem Biol Drug Des; 2019 Oct; 94(4):1813-1823. PubMed ID: 31260185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
    Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
    Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.
    Ramalingam S; Gediya L; Kwegyir-Afful AK; Ramamurthy VP; Purushottamachar P; Mbatia H; Njar VC
    Oncotarget; 2014 Jan; 5(2):530-43. PubMed ID: 24504069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.
    Ueda T; Watanabe-Fukunaga R; Fukuyama H; Nagata S; Fukunaga R
    Mol Cell Biol; 2004 Aug; 24(15):6539-49. PubMed ID: 15254222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
    Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
    Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction.
    Shveygert M; Kaiser C; Bradrick SS; Gromeier M
    Mol Cell Biol; 2010 Nov; 30(21):5160-7. PubMed ID: 20823271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
    Yuan X; Wu H; Bu H; Zheng P; Zhou J; Zhang H
    Bioorg Med Chem; 2019 Apr; 27(7):1211-1225. PubMed ID: 30824167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations.
    Kannan S; Poulsen A; Yang HY; Ho M; Ang SH; Eldwin TS; Jeyaraj DA; Chennamaneni LR; Liu B; Hill J; Verma CS; Nacro K
    Biochemistry; 2015 Jan; 54(1):32-46. PubMed ID: 25431995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
    Teo T; Yang Y; Yu M; Basnet SK; Gillam T; Hou J; Schmid RM; Kumarasiri M; Diab S; Albrecht H; Sykes MJ; Wang S
    Eur J Med Chem; 2015 Oct; 103():539-50. PubMed ID: 26408454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.
    Basnet SK; Diab S; Schmid R; Yu M; Yang Y; Gillam TA; Teo T; Li P; Peat T; Albrecht H; Wang S
    Mol Pharmacol; 2015 Nov; 88(5):935-48. PubMed ID: 26268528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.
    Xie J; Shen K; Jones AT; Yang J; Tee AR; Shen MH; Yu M; Irani S; Wong D; Merrett JE; Lenchine RV; De Poi S; Jensen KB; Trim PJ; Snel MF; Kamei M; Martin SK; Fitter S; Tian S; Wang X; Butler LM; Zannettino ACW; Proud CG
    Cell Mol Life Sci; 2021 Jan; 78(1):249-270. PubMed ID: 32170339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Mnks for cancer therapy.
    Hou J; Lam F; Proud C; Wang S
    Oncotarget; 2012 Feb; 3(2):118-31. PubMed ID: 22392765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
    Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
    J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.
    Waskiewicz AJ; Flynn A; Proud CG; Cooper JA
    EMBO J; 1997 Apr; 16(8):1909-20. PubMed ID: 9155017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
    Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
    PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.